John Patton, Head of Kindeva Drug Delivery’s Scientific Advisory Board, Named Winner of RDD Conference’s Charles G. Thiel Award
At the recent Respiratory Drug Delivery (RDD) Conference, John Patton, Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, was announced as the winner of the Charles G. Thiel Award. This prestigious award is given once every two years at RDD Conferences to one scientist who has been voted by his or her peers to have pioneered significant developments in one or more aspects of the science and technology surrounding respiratory drug delivery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508931671/en/
Biotechnology scientist and entrepreneur and Kindeva Drug Delivery’s Head of the Scientific Advisory Board, John Patton (second from the left), was named the winner of the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery at this year’s Respiratory Drug Delivery (RDD) Conference. Also pictured (from left to right): Michael Hindle, Ph.D., Professor, School of Pharmacy at Virginia Commonwealth University, Stephen Stein, Scientific Director of Inhalation Product Development at Kindeva, and Milton Boyer, CEO at Kindeva. (Photo: Business Wire)
Patton has been one of the most influential scientists in the field of respiratory drug delivery and is a champion in the field of pulmonary delivery of large molecules and biologics. He has published more than 100 publications, has more than 40 patents, and has founded or co-founded six drug delivery companies, including iPharma Labs, a company that Kindeva acquired in 2022.
“John’s research and development expertise, coupled with the myriad publications he authored, have helped pave the way for respiratory delivery to be utilized by researchers and companies for the treatment of other diseases,” said Kindeva’s Global Chief Commercial Officer, David Stevens. “John’s passion and conviction with respect to the applications of drug delivery to and through the lungs, and in particular his pioneering work progressing pulmonary delivery of biologics, has been nothing short of inspiring. John has made and continues to make a tremendous contribution to both Kindeva and the wider industry. On behalf of all his colleagues at Kindeva, we congratulate John. It is a privilege to work alongside him and benefit from his technical vision and boundless enthusiasm for inhaled medicine.”
Kindeva’s application in inhaled biologics spans complex therapeutic treatments from local to deep lung (systemic) delivery — including lung fibrosis, asthma/COPD, cardiovascular, and infectious diseases — and encompasses a wealth of expertise in developing solutions that address insulin needs, cold chain requirements, and more.
Read more about this award as well as Kindeva’s advancements in biologic drug development.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508931671/en/
Contact information
MEDIA CONTACT:
Lindsey Langemeier
+1 402-405-4269
pr@scorrmarketing.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citco Grows Asia Pacific Presence With New Japan Office12.11.2024 17:30:00 CET | Press Release
The Citco group of companies (Citco), the leading asset-servicer to the alternative investment sector, has announced the launch of Citco Japan Co KK. This new entity in Japan underscores Citco’s commitment to the Asia- Pacific region and bolsters its global offering to both current and prospective clients. Citco has over $2 trillion in assets under administration (AuA) and offers a full suite of middle-office and back-office services to alternative investment companies across the globe. These services include fund accounting, treasury and loan handling, investor services, corporate services, regulatory and risk reporting, banking solutions, and tax and financial reporting services, among others. Citco Japan Co KK is situated in Grantokyo South Tower 11F, 1-9-2 Marunouchi Chiyoda-Ku, Tokyo, 100-6611, Japan, and will operate as Citco’s local operational headquarters in the region. The team will offer fund accounting, fund operations and Special Purpose Vehicle (SPV) administration servic
Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow12.11.2024 17:00:00 CET | Press Release
To facilitate large-scale production of peptide drugs, Asymchem (stock codes: 002821.SZ/6821.HK), a leading global pharmaceutical contract development and manufacturing organization (CDMO), has achieved fully automated manufacturing. One initial hurdle was equipment scale-up. In particular, the optimal suspension and mixing of resin with reactants and the structural design of the synthesizer required careful attention. To address this, Asymchem’s Chemical Engineering Department (CED) utilized advanced simulation techniques and experimental validation to finalize the solid-phase synthesizer design and define the stirring paddles’ structural characteristics. The new structure is in the patent application process and is planned to be scaled up for use in 2000-liter solid-phase synthesizer equipment. The implementation of an automated formulation system was an additional challenge. Asymchem achieved this and additionally developed a host computer system that seamlessly interfaces with the
BST Global Launches AI + Data Impact Survey for the AEC Industry12.11.2024 16:41:00 CET | Press Release
BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its groundbreaking AI + Data Survey globally. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 13, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112980057/en/ BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its groundbreaking AI + Data Survey globally. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 13, 2024. (Graphic: BST Global) BST Global partnered with BST Global’s AI + Data Consortium and the American Council of Engineering Companies' (ACEC) Technology Committ
Medidata and Bioforum Bolster Decade-Long Relationship to Advance Clinical Data and Biometric Solutions for Clinical Trials12.11.2024 16:40:00 CET | Press Release
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a biometrics CRO that serves clinical trial sponsors worldwide. Building on more than a decade of collaboration, the expanded partnership provides Bioforum’s biotech customers with broader access to Medidata’s AI-powered technology, enabling a more agile clinical development experience. In addition to Medidata solutions such as Medidata Rave EDC and Medidata Rave RTSM, which Bioforum has leveraged to deliver 60 studies across a range of therapeutic areas, the CRO is adding Medidata Clinical Data Studio and Medidata eConsent to streamline data flow, maintain data integrity, and ensure compliance. “With our team of experts, industry-leading biometric services, and proprietary technology, Bioforum empowers sponsors to seamlessly manage their clinical data in one place and ensure it’s secure, accurate, and ready for an
ATRC’s VentureOne Launches QuantumGate to Secure Data for the Quantum Era at CyberQ12.11.2024 16:37:00 CET | Press Release
The Advanced Technology Research Council’s commercialization arm, VentureOne, has launched QuantumGate, a new venture that offers a suite of advanced data security products to protect organizations’ data assets in the quantum era, at CyberQ in Abu Dhabi today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112430830/en/ ATRC’s VentureOne Launches QuantumGate to Secure Data for the Quantum Era at CyberQ (Photo: AETOSWire) H.E. Faisal Al Bannai, the Secretary General of ATRC, said, “The quantum era isn’t a distant threat—it is here. The launch of QuantumGate is a pivotal step in safeguarding invaluable data assets against ever-increasing cybersecurity threats. QuantumGate’s sovereign solutions will ensure our country’s and our organizations’ sensitive information stays safe.” “Cryptographic algorithms are used by virtually all organizations to encrypt and protect data,” said Dr. Najwa Aaraj, the CEO of the Technology Innova
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom